Welcome to our dedicated page for Prestige Consmr Healthcare SEC filings (Ticker: PBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prestige Consumer Healthcare Inc. filings document material events for an operating consumer healthcare company, including 8-K disclosures on quarterly and year-to-date operating results, financial condition and Regulation FD investor presentations. The filings also cover material agreements, capital-structure matters, governance topics and shareholder voting matters tied to the company’s public-company reporting.
These records frame Prestige’s disclosures around its portfolio of over-the-counter healthcare brands, retail distribution markets, and product or regulatory matters when they are material to the business.
Ariel Investments, LLC has reported beneficial ownership of 4,102,497 shares of Prestige Consumer Healthcare Inc common stock, representing 8.5% of the outstanding class as of December 31, 2025. Ariel has sole voting power over 3,672,254 shares and sole dispositive power over all 4,102,497 shares.
The filing explains that these securities are held for Ariel’s adviser clients, who are entitled to dividends and sale proceeds, and that no individual client has an economic interest in more than 5% of the shares. Ariel certifies the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Prestige Consumer Healthcare.
A person associated with PBH has filed a notice of intent to sell 1,000 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 65,930.00. The filing shows 47,318,730 shares of this class outstanding. The shares to be sold were acquired through restricted stock vesting on May 2, 2024, May 5, 2025, and May 7, 2025, in amounts of 116, 533, and 351 shares respectively, all as compensation. Over the past three months, the filer previously sold 719 shares on November 28, 2025 for gross proceeds of 43,140.00 and 281 shares on December 1, 2025 for gross proceeds of 16,860.00.
Prestige Consumer Healthcare Inc. reported softer results for the quarter ended December 31, 2025. Total revenues slipped 2.4% to $283.4 million, with declines in both North American and International OTC segments, mainly from weaker Eye & Ear Care sales. Quarterly net income fell to $46.7 million, or $0.97 per diluted share, down from $61.0 million and $1.22 a year earlier, reflecting lower sales, higher general and administrative costs and a $10.3 million supplier loan write-off.
For the first nine months of fiscal 2026, revenues declined 4.1% to $807.1 million and net income decreased to $136.4 million from $164.5 million, while gross margin ticked higher on favorable mix. The company completed two acquisitions, including Pillar5 Pharma for a preliminary $111.9 million, added goodwill and intangibles, generated strong operating cash flow of $214.8 million, and used $155.6 million to repurchase shares, ending with $62.4 million in cash and $1.04 billion of long-term debt.
Prestige Consumer Healthcare Inc. filed a current report to share that it has announced financial results for the fiscal quarter and nine months ended December 31, 2025. The detailed numbers are provided in a separate earnings press release attached as Exhibit 99.1.
The company is also using an investor presentation, attached as Exhibit 99.2, to discuss these results with investors, analysts and others during the fiscal year ending March 31, 2026. Both the press release and presentation are being treated as “furnished,” meaning they are provided for information and are not classified as formally filed financial statements under securities laws.
Prestige Consumer Healthcare senior vice president Jose Luis Rosado reported receiving 3,426 shares of common stock on January 6, 2026, at a price of $0 per share, bringing his direct holdings to 3,436 shares.
The award represents restricted stock units that are scheduled to fully vest on January 6, 2030, indicating a long-term, equity-based component to his compensation aligned with the company’s future performance.
Prestige Consumer Healthcare executive Jose Luis Rosado filed an initial insider ownership report. As of January 6, 2026, he beneficially owns 10 shares of common stock, held directly. Rosado serves as SVP – Quality & Regulatory Affairs. No derivative securities are reported.
Prestige Consumer Healthcare Inc. officer Jeffrey Zerillo, Senior VP Operations, reported two open-market sales of company stock. On 11/28/2025, he sold 719 shares of common stock at $60 per share, leaving him with 42,329 shares beneficially owned afterward. On 12/01/2025, he sold an additional 281 shares at $60 per share, reducing his holdings to 42,048 shares.
The filing is a Form 4, which discloses changes in ownership by company insiders and confirms that Zerillo’s holdings remain directly owned after these transactions.
An affiliate of PBH has filed a Rule 144 notice to sell 281 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $16,860.00. The filing shows that 48,084,010 shares of this class were outstanding at the time of the notice, providing a baseline for the issuer’s equity size.
The shares to be sold were originally acquired on 05/04/2023 through restricted stock vesting from the issuer as compensation, rather than a cash purchase. The seller, Jeffrey A. Zerillo, also sold 719 shares of common stock on 11/28/2025 for $43,140.00 during the prior three months, as disclosed in the same notice.
PBH has a holder planning to sell 719 shares of its common stock under Rule 144. The planned sale is through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 11/28/2025 and an aggregate market value of 43140.00.
The securities being sold were acquired through restricted stock vesting from the issuer on 05/02/2025 and 05/05/2025, in amounts of 673 and 46 shares as compensation. As context, the number of shares of PBH common stock outstanding is reported as 48084010.
Prestige Consumer Healthcare Inc. (PBH) director John E. Byom reported a sale of company stock. On 11/25/2025, he sold 3,000 shares of common stock at a price of $59.35 per share in a single reported transaction where multiple lots at the same price were combined. After this sale, he beneficially owns 51,594 shares, held directly. The filing is made on Form 4, which reports changes in the ownership of company equity by an insider who serves as a director.